Cerevel Therapeutics Holdings, Inc.
NASDAQ: CERE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ronald C. Renaud Jr.,
- Employees
- 355
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Market cap
- $8.2B
- Website
- https://www.cerevel.com
Loading CERE…
Loading profile data…Frequently asked questions about CERE
What does Cerevel Therapeutics Holdings, Inc. (CERE) do?
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) i...
Where does CERE trade?
Cerevel Therapeutics Holdings, Inc. (CERE) trades on the NASDAQ Capital Market.
What sector is CERE in?
Cerevel Therapeutics Holdings, Inc. (CERE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cerevel Therapeutics Holdings, Inc.?
Ronald C. Renaud Jr., is the chief executive officer of Cerevel Therapeutics Holdings, Inc. (CERE).
Where is Cerevel Therapeutics Holdings, Inc. headquartered?
Cerevel Therapeutics Holdings, Inc. is headquartered in United States.
Does CERE pay a dividend?
Cerevel Therapeutics Holdings, Inc. (CERE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CERE go public?
Cerevel Therapeutics Holdings, Inc. (CERE) completed its initial public offering in 2020.